)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Daiichi Sankyo Company
Daiichi Sankyo Company (4568) investor relations material
Daiichi Sankyo Company Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2027 earnings summary30 Oct, 2026
Executive summary
H1 FY2026 revenue rose 19.7% YoY to ¥1,167.2bn, led by ENHERTU and DATROWAY growth and favorable FX.
Core operating profit increased 46.9% to ¥221.3bn; operating profit rose 34.4% to ¥193.8bn, while FY2026 guidance remained unchanged.
Financial highlights
Revenue increased ¥191.9bn YoY; FX contributed ¥73.9bn and revenue excluding FX rose ¥118.0bn.
Profit attributable to owners rose 15.8% to ¥151.5bn; profit before tax increased 18.2% to ¥192.9bn.
Basic EPS was ¥83.22 versus ¥70.55 a year earlier; diluted EPS was ¥83.20 versus ¥70.52.
ENHERTU and DATROWAY global product sales reached ¥464.5bn and ¥48.3bn, up 45.9% and 207.2%, respectively.
Cost of sales rose ¥1.1bn to ¥239.8bn despite revenue growth; the COGS ratio improved.
Outlook and guidance
FY2026 guidance was unchanged: revenue ¥2,340bn, core operating profit ¥360bn, operating profit ¥320bn and profit attributable to owners ¥251bn.
ENHERTU FY2026 sales forecast rose ¥20.5bn to ¥915.3bn and DATROWAY forecast rose ¥2.0bn to ¥118.9bn.
FY2026 CMO compensation fee forecast remained ¥80.0bn; provisions related to CY2028 are expected in Q3 or later.
Q4 is expected to be weaker than Q3 on seasonality, with higher expenses and the ¥80bn CMO charge more likely in Q4; more than ¥90bn of ENHERTU sales milestones is expected in Q4.
TROPION-Lung15 readout is expected in FY2026 H2, AVANZAR in CY2027 H1 and TROPION-Lung07 in H1 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Daiichi Sankyo Company
- ADC-based regimens show strong efficacy and safety in advanced and perioperative NSCLC.4568
WCLC/ESMO 2024 Conference - Q1 FY2026 revenue up 21.1% YoY, guidance raised, but profit fell on higher costs.4568Q1 2027
- Oncology-driven revenue and profit growth, robust outlook, and higher dividend planned.4568Q3 2026
- Oncology-driven revenue growth offset by higher costs and revised profit guidance.4568Q2 2026
- T-DXd delivers robust efficacy and safety in HER2-low/ultralow breast cancer, expanding treatment options.4568Status Update
- Multiple new oncology launches and clinical catalysts set to triple eligible patients by 2026.4568Status Update
- ENHERTU® and DXd ADCs drive clinical, regulatory, and supply advances, expanding global impact.4568Status Update
- ENHERTU-driven oncology and FX gains fueled record revenue and profit growth.4568Q1 2025
- Record profit and revenue growth driven by oncology, with higher dividends and buybacks ahead.4568Q4 2025
Next Daiichi Sankyo Company earnings date
Investor Day 202625 Nov, 2026
Daiichi Sankyo Company
Next Daiichi Sankyo Company earnings date
Investor Day 202625 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Daiichi Sankyo Company Limited is a global pharmaceutical company, focusing on the research, development, manufacturing, and marketing of pharmaceutical products. The company operates in the healthcare sector, providing drugs and services in various therapeutic areas, including cardiovascular, oncology, and metabolic disorders, among others. Daiichi Sankyo's approach combines expertise in biologics with advanced research technologies to develop novel therapies and solutions for patients worldwide. The company is headquartered in Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.